Connect Biopharma is transitioning from clinical-stage uncertainty to regulatory readiness and commercial preparation. With a robust cash position and promising Phase 2 data in asthma and dermatitis, it offers considerable upside if trials succeed and licensing progress continues.
CNTB Bull Make a Statement
Updated: 7/17/2025 9:07 PM
Bottom Line: Looking wave 3 impulse continuation.
(Last Price 3.02): Wave 3 impulse breakout solidified by higher high, our focus is high for wave 3, since japaulgold has printed multiple nested impulses, we expect a significant rally..
(Last Price 3.02): Daily -Wave 3 impulse breakout solidified by higher high, our focus is high for wave 3, since japaulgold has printed multiple nested impulses, we expect a significant rally..
(Last Price 3.02): Weekly -Wave 3 impulse breakout solidified by higher high, our focus is high for wave 3, since japaulgold has printed multiple nested impulses, we expect a significant rally..